FG receives long-acting injectable Lenacapavir for HIV prevention


Posted on: Thu 12-03-2026

The Federal Government has received supplies of the long-acting injectable drug Lenacapavir for use as Pre-Exposure Prophylaxis (PrEP), in a move aimed at strengthening the country’s HIV prevention strategy and expanding available options for people at risk of infection.

The government said the introduction of the injectable PrEP will complement existing prevention services and support Nigeria’s broader response to HIV/AIDS, particularly among vulnerable populations who may struggle with daily oral medication.

Officials disclosed that preparatory activities for the rollout have been completed, including landscape and readiness assessments conducted across 10 states — Akwa Ibom State, Anambra State, Benue State, Cross River State, Ebonyi State, the Federal Capital Territory, Gombe State, Kano State, Kwara State, and Lagos State.

The National Coordinator of the National AIDS, Viral Hepatitis and STIs Control Programme (NASCP) under the Federal Ministry of Health and Social Welfare, Mr. Adebobola Bashorun, disclosed this in a statement issued in Abuja.

Bashorun described the introduction of Lenacapavir for PrEP as a major milestone in expanding prevention choices, noting that the long-acting injectable option is expected to improve adherence and increase access to effective HIV prevention services.

“This milestone, approved by the Coordinating Minister of Health and Social Welfare and supported through the Global Fund, represents a significant advancement in Nigeria’s HIV prevention efforts and reinforces the country’s commitment to expanding innovative prevention options,” he said.

According to him, the arrival of Lenacapavir reflects Nigeria’s determination to deploy evidence-based and innovative interventions to accelerate progress toward controlling the HIV epidemic.

He added that NASCP, in collaboration with development partners and stakeholders, will ensure the safe introduction, strategic deployment, and effective integration of the injectable drug into the national HIV prevention framework.

Bashorun emphasised that the rollout demonstrates Nigeria’s resolve to scale up innovative solutions in the fight against HIV, noting that the programme remains committed to expanding equitable access to prevention, testing, treatment, and care services across the country.